MedPath

Control of Iatrogenic Endobronchial Bleeding by Tranexamic Acid, Adrenalin and Hemagglutinase

Early Phase 1
Recruiting
Conditions
Iatrogenic Endobronchial Bleeding
Interventions
Drug: Tranexamic Acid;
Drug: Hemagglutinase
Registration Number
NCT06149091
Lead Sponsor
China-Japan Friendship Hospital
Brief Summary

A prospective national multi-center study will be conducted to evaluate the effectiveness of hemocoagulase in iatrogenic airway bleeding in a large class III hospital, such as the Second Affiliated Hospital of Harbin Medical University, the First Affiliated Hospital of Nanchang University, and to compare it with topical epinephrine and tranexamic acid in a prospective double-blind cluster randomized controlled trial.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
300
Inclusion Criteria
  • During diagnostic bronchoscopy, patients with bronchial bleeding that was not successfully controlled with cold (4°C) saline (3 times within 60 seconds, 5ml each time).
Exclusion Criteria
  • 1: Patients with contraindications for diagnostic flexible bronchoscopy.

    2: Coagulopathy (PV INR >1.3).

    3: Thrombocytopenia (<50x10^9) or anemia (hgb <80 g/L).

    4: Direct oral anticoagulant, low molecular weight heparin, or antiplatelet therapy.

    5: Thrombophilia, history of pulmonary embolism or deep vein thrombosis.

    6: Contraindications for the use of epinephrine in the bronchus.

    7: Coronary artery disease, cerebrovascular disease, history of rapid arrhythmias.

    8: Uncontrolled pulmonary hypertension.

    9: Cardiovascular decompensation.

    10: Severe hypoxia (PaO2 <60mmHg, SaO2 <90%, FiO2 >=60%).

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Tranexamic Acid GroupTranexamic Acid;Patients with iatrogenic airway bleeding who were randomly assigned to the group and failed to achieve hemostasis after three applications of cold saline within a given week were treated with tranexamic acid for hemostasis.
Hemagglutinase GroupHemagglutinasePatients with iatrogenic airway bleeding who were randomly assigned to the group and failed to achieve hemostasis after three applications of cold saline within a given week were treated with Hemagglutinase for hemostasis.
Adrenalin GroupAdrenalinPatients with iatrogenic airway bleeding who were randomly assigned to the group and failed to achieve hemostasis after three applications of cold saline within a given week were treated with Adrenalin for hemostasis.
Primary Outcome Measures
NameTimeMethod
Intratracheal bleeding control rateUp to a single examination, no more than 1 minute after each drug application. Under bronchoscopy, physicians visually assess clot formation to evaluate bleeding control

The percentage of iatrogenic bronchial bleeding successfully controlled in each group (%)

Secondary Outcome Measures
NameTimeMethod
Number of tranexamic acid/adrenaline/thrombin applications required to control bronchial bleedingUntil the end of a single procedure (bronchoscopy), up to 1 minute after each drug application.

Number of tranexamic acid/adrenaline/thrombin applications required to control bronchial bleeding

Number of recurrent bleeding episodes after infusion of tranexamic acid/adrenaline/thrombin (N)Within 24 hours after a single procedure (bronchoscopy)

Number of recurrent bleeding episodes after infusion of tranexamic acid/adrenaline/thrombin (N)

Percentage (%) of iatrogenic bronchial bleeding successfully controlled in each group in relation to the severity of the bleeding.Up to the end of a single procedure (bronchoscopy), a maximum of 1 minute after each drug application.

Percentage (%) of iatrogenic bronchial bleeding successfully controlled in each group in relation to the severity of the bleeding. Bronchoscopic physicians assess using a Visual Analog Scale (VAS) 1-10 (1 very mild - 10 very severe)

Trial Locations

Locations (1)

China-Japan Friendship Hospital

🇨🇳

BeiJing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath